TY  - JOUR
A1  - Darlix, Amélie
A1  - Mandonnet, Emmanuel
A1  - Freyschlag, Christian Franz
A1  - Pinggera, Daniel
A1  - Forster, Marie-Thérèse
A1  - Voß, Martin
A1  - Steinbach, Joachim Peter
A1  - Loughrey, Carmel
A1  - Goodden, John
A1  - Banna, Giuseppe
A1  - Di Blasi, Concetta
A1  - Foroglou, Nicolas
A1  - Hottinger, Andreas F.
A1  - Baron, Marie-Hélène
A1  - Pallud, Johan
A1  - Duffau, Hugues
A1  - Rutten, Geert-Jan
A1  - Almairac, Fabien
A1  - Fontaine, Denys
A1  - Taillandier, Luc
A1  - Viegas, Catarina
A1  - Albuquerque, Luisa
A1  - Campe, Gord von
A1  - Urbanic Purkart, Tadeja
A1  - Blonski, Marie
T1  - Chemotherapy and diffuse low-grade gliomas : a survey within the European Low-Grade Glioma Network
T2  - Neuro-oncology practice
N2  - Background: Diffuse low-grade gliomas (DLGGs) are rare and incurable tumors. Whereas maximal safe, functional-based surgical resection is the first-line treatment, the timing and choice of further treatments (chemotherapy, radiation therapy, or combined treatments) remain controversial.
Methods: An online survey on the management of DLGG patients was sent to 28 expert centers from the European Low-Grade Glioma Network (ELGGN) in May 2015. It contained 40 specific questions addressing the modalities of use of chemotherapy in these patients.
Results: The survey demonstrated a significant heterogeneity in practice regarding the initial management of DLGG patients and the use of chemotherapy. Interestingly, radiation therapy combined with the procarbazine, CCNU (lomustine), and vincristine regimen has not imposed itself as the gold-standard treatment after surgery, despite the results of the Radiation Therapy Oncology Group 9802 study. Temozolomide is largely used as first-line treatment after surgical resection for high-risk DLGG patients, or at progression.
Conclusions: The heterogeneity in the management of patients with DLGG demonstrates that many questions regarding the postoperative strategy and the use of chemotherapy remain unanswered. Our survey reveals a high recruitment potential within the ELGGN for retrospective or prospective studies to generate new data regarding these issues.
KW  - diffuse low-grade glioma
KW  - clinical practice
KW  - chemotherapy
KW  - PCV
KW  - temozolomide
Y1  - 2018
UR  - http://publikationen.ub.uni-frankfurt.de/frontdoor/index/index/docId/50862
UR  - https://nbn-resolving.org/urn:nbn:de:hebis:30:3-508621
SN  - 2054-2585
SN  - 2054-2577
N1  - This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
VL  - 6
IS  - 4
SP  - 264
EP  - 273
PB  - Oxford Univ. Press
CY  - Oxford
ER  -